The U.S. Food and Drug Administration (FDA) has officially reversed its earlier stance, agreeing to review Moderna’s messenger RNA (mRNA)…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands Compared
The relentless pursuit of efficiency and patient safety in healthcare has driven a significant transformation within pharmacy operations, making the…
Read More
OrsoBio’s LXR inverse agonist shows promise for hard-to-treat triglyceride disorders and pioneering a new frontier in obesity therapeutics
OrsoBio, a dynamic biotech enterprise dedicated to advancing novel therapies for obesity and a spectrum of obesity-related metabolic disorders, is…
Read More
Sai Life Sciences plans to recruit 700+ professionals in FY27 as Indian CRDMO demand accelerates
Sai Life Sciences, a prominent Contract Research, Development & Manufacturing Organization (CRDMO) based in Hyderabad, India, has announced an ambitious…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read More
Closing the Information Gap: ETH Zurich Team Integrates Function and Binding in One Drug Screening Assay
A groundbreaking collaborative effort between researchers at ETH Zurich and Karolinska Institutet has culminated in the development of a novel…
Read More
Can live cell dynamics fix drug discovery’s efficacy problem?
The pharmaceutical industry faces a profound and escalating crisis marked by soaring costs, protracted timelines, and persistently high failure rates…
Read More
From list price to net price: How finance leaders decode real drug costs
In the intricate landscape of the healthcare industry, discussions surrounding drug pricing frequently commence and conclude with the list price.…
Read MoreYOU MAY HAVE MISSED
